3 PD can occur at any age, but most commonly, patients are in their fifth decade of life. The prevalence rates are unclear and vary between 0.39% and 22.5%. 1, 2 Patients usually seek medical care for pain during erection or penile deformity. In one report, a spontaneous improvement was observed in 12% of patients, stabilization in 67%, and worsening of symptoms in 21%. Peyronie's disease (PD) is characterized by an initial acute painful inflammatory phase followed by a chronic stage where the plaque stabilizes. Younger age and concomitant use of PDE5i were the only success predictors. LiESWT had a favorable impact on Lue score and notably penile pain, curvature, plaque size, and erectile function in patients treated for PD during the early inflammatory phase, with no side effects. On univariate and multivariate analysis, the only predictors of success were younger age (odds ratio = 0.95, P = 0.03 and OR = 0.91, P = 0.04, respectively) and concomitant use of phosphodiesterase-5 inhibitors (PDE5i OR = 0.92, P = 0.02 and OR = 0.93, P = 0.01, respectively). After treatment, the median Lue score decreased from 6.8 initially to 3.3 ( P = 0.003), the median Likert pain score dropped from 1.8 to 0.7 ( P = 0.004), the median plaque size was reduced from 2 cm to 1.2 cm ( P = 0.08), and the median penile curvature diminished from 31° to 17° ( P = 0.07). The median number of sessions received per patient was 7.2. We included 39 patients (median age: 56.8 years, interquartile range : 35.8–62.2 years). The protocol consisted of 6 weekly sessions of 4000 pulses each, applied from different directions, with a maximal power of 20 W and 8 Hz frequency. Patients in acute phase of PD and an angulation of <40° were included. Age, characteristics of fibrous plaques, concomitant treatments, International Index of Erectile Function (IIEF-5), Lue score, and pain score on Likert scale were collected. Patients treated for PD were prospectively recorded, and data were retrospectively reviewed. In this regard, we have paid particular attention to the development of different focus zones in size/volume, thickness, and penetration depth.įor example, on the basis of single and double layer piezo technologies we have developed unique linear focusing therapy sources that allow a significantly larger treatment volume.The aim of this article is to assess the outcomes of a low-intensity extracorporeal shock wave therapy (LiESWT) protocol for the treatment of Peyronie's disease (PD). Consequently, we have consistently worked on further developments and innovations that enable new and extended areas of application. The focused piezo shockwave, with its unique properties, is one of today's best-selling shockwave systems worldwide. With this mobile therapy unit you can optionally choose between the classic point-focused, the linear focused shockwave, as well as the planar shockwave. The piezoelectric shockwave principle allows a unique variability of the shockwave modulation. Compared to conventional, point-focused shockwaves, a much more homogeneous and effective application is made possible. The current development of a linear focusing shockwave therapy source is unique worldwide. Based on piezo single and double surface technology, a worldwide-unique and excluxive, optional variation of the therapy sources is achieved. Unique, new and improved features characterize the next generation of piezo shockwave devices from Richard Wolf and ELvation® Medical.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |